BioAge Labs Plunges 62% After Novo Nordisk's NLRP3 Trial Failure Casts Doubt on Pipeline
BIOA has more than doubled off its 52-week low of $4.11 on elevated volume (11× avg).
Summary
BioAge Labs shares crashed 61.73% after Novo Nordisk's Phase 3 ZEUS trial of ziltivekimab, an NLRP3 inhibitor, failed to reduce cardiovascular events. The result directly threatens BioAge's lead candidate BGE-102, another NLRP3 inhibitor in Phase 2 for cardiovascular disease. William Blair analyst Andy Hsieh noted the failure undermines the hypothesis that large hsCRP reductions translate to MACE protection, and suggested investors may write off BioAge's NLRP3 opportunity. BioAge's QUELL-CV trial data is expected in H2 2026, but the investment thesis is now severely damaged. Neumora Therapeutics, developing the CNS-penetrating NLRP3 inhibitor NMRA-215, also traded lower in sympathy, though its program is earlier-stage with a first-in-human trial planned by end-2026.
At the time of this announcement, BIOA was trading at $9.58 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.1B. The 52-week trading range was $4.11 to $25.96. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Benzinga.